Dr. David T. Pride, MD, PHD
Infectious Disease (Infectious Disease Physician)
200 W Arbor Dr, University Of California San Diego Medical Center
San Diego, CA 92103
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2007
Licensed in California since 2005, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
CA license A91401 (first issued 2005; current) -
Internal Medicine Physician
CA license A91401 (first issued 2005; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 4 companies reported 7 payments worth $3,661 in total to this clinician.
| Cepheid | $3,200 |
|---|---|
| Gen-probe, Inc. | $400 |
| Genmark Diagnostics, Inc. | $40.21 |
| Roche Diagnostics Corporation | $20.81 |
| Speaking at a medical education program | $3,167 |
|---|---|
| Consulting Fee | $400 |
| Food and Beverage | $93.55 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Cepheid Dec 16, 2025 | Speaking at a medical education program GeneXpert · Devices | $2,167 |
| Cepheid Nov 21, 2025 | Speaking at a medical education program GeneXpert · Devices | $500 |
| Cepheid Dec 11, 2025 | Speaking at a medical education program GeneXpert · Devices | $500 |
| Gen-probe, Inc. Jul 1, 2025 | Consulting Fee NONE · Diagnostics Company’s description1042142 | $400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $1,419,001 in research payments for these studies, mostly to the institutions running them.
- CTP0030
Genmark Diagnostics, Inc. - Performance Evaluation of the VIDAS TB-IGRA Assay.
Biomerieux Inc · Completed · NCT04048018 - Study name not reported
Gen-probe, Inc. - CTP0011
Genmark Diagnostics, Inc. - Clinical Performance Evaluation of Viral Load Assays for the Detection and Quantitation of HIV-1, HCV and HBV in Plasma Samples Tested on Aptima, Alinity m, and cobas (5800)
Gen-probe, Inc. - CTP0028
Genmark Diagnostics, Inc. - RD006591: Trichomonas and Mycoplasma prevalence in Southern California populations.
Roche Diagnostics Corporation - CTP0023
Genmark Diagnostics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.